Press Releases DBV Technologies

Equities

DBV

FR0010417345

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:25:00 05/06/2026 pm IST			5-day change	1st Jan Change
2.852 ^EUR	-5.12%		-15.12%	-15.62%

05/06	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week	MT
04/06	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

Press Releases

06/06	DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	GL
04/06	AGM 2026: Attendance Summary Report (DBV 2026 ARRETE DE FEUILLE DE PRESENCE SIGNEE)	PU
04/06	AGM 2026: Results of the AGM votes (DBV 2026 VOTING RESULTS EN)	PU
04/06	DBV Technologies Announces the Results of its 2026 Combined General Meeting	GL
03/06	DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy	GL
14/05	Combined General Meeting of June 3, 2026	GL
13/05	DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq	GL
01/05	DBV Technologies Reports First Quarter 2026 Financial Results	GL
27/03	DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document	GL
27/03	DBV Technologies Reports Full Year 2025 Financial Results and Business Update	GL
25/03	DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review	GL
13/03	Euronext announces March 2026 quarterly review results of the CAC Family	AQ
05/03	DBV Technologies to Participate in Upcoming March Investor Conferences	GL
02/03	DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting	AQ
01/03	DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting	GL
11/02	DBV Technologies : to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting	PU
11/02	DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting	GL
10/02	DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook, Biotech Summit	AQ
10/02	DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit	GL
17/01	DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing	GL
08/01	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF	GL
17/12	DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years	AQ
17/12	DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years	GL
12/11	DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years	GL
12/11	DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years	AQ